Skip to main content
Equibles
RNA logo

RNA · Atrium Therapeutics, Inc.

Track RNA — free

Use RNA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RNA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$8.16 -0.10 (-1.21%)
Russell 2000 member Rebalance outlook locked
Market Cap
$141.29M
Shares
17.11M
Volume · Oct 8 649.31K Avg daily vol (3M) 259.18K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$8.26 Open$8.15 Day$7.97–8.33 Available close range$7.84–16.54 Avg vol 30d382K Short int3.4M · 19.9% float · 8.2d Short vol53% Last earningsAug 13, 2026 DataFeb 2026–Oct 2026 Filing10-Q · Aug 13

The closing range uses available history since Feb 27, 2026; less than a full year is stored.

Up next

Latest filing: 10-Q
filed Aug 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
-21.9%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$263.90M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.0%
Year over year
Price change (1Y)
—
Trailing year
Short interest
19.9%
Latest settlement · 8.2 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 15.4 · calm Equity put/call 0.62
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 50-day avg −26%
below
RSI (14) 32
neutral
MACD trend Positive
52-week position 5%
near low
Momentum
relative strength
Very Weak
1-month return −20%
trailing
6-month return −43%
trailing
Relative strength −52%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
4 of 156 funds reported for Sep 30 · net +698 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
19.86% of float · ▲ +1.4% MoM · 8.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
156 holders — 13F breadth
Squeeze score 71
high risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 53%
annualized · 1-yr
Max drawdown −53%
past year
ATR 6.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
−26% Bearish
RSI (14)
32 Neutral
MACD trend
Positive Bullish
52-week position
5% Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
4 of 156 funds reported for Sep 30 · net +698 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
19.86% of float · ▲ +1.4% MoM · 8.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
156 holders — 13F breadth
Price context
position in its available closing range
Range low $8 Now $8 · 5% Range high $17
vs 50-day avg -26%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
RNA
Atrium Therapeutics, Inc.
this stock
$141.29M — — — 19.9%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $127.55B +11.0% +46.2% 29.3 1.9%
MRNA
Moderna, Inc.
 $78.65B +568.0% +4.3% — 8.2%
REGN
Regeneron Pharmaceuticals, Inc.
 $76.14B -4.2% +20.8% 18.3 2.5%
CSLLY
Csl Ltd
 $60.24B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
155
% held
89.2%
Reported
4 of 156
Top holder
Sessa Capital IM, L.P.
Held Float
View
Held by Funds
Fund positions
150
View
Short & Settlement
Short Interest Rising
Shares short
3.4M
Days to cover
8.2d
Change
+46.3K sh
View
Short Volume
Short vol %
53%
As of
Oct 8, 2026
Short Total
View
Fails to Deliver
FTD shares
48
Value
$504
As of
Sep 10, 2026
View
Off-Exchange
Off-exchange %
42.8%
Week of
Aug 31, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
8-K/A
Filed
Oct 9, 2026
This year
10
View
Earnings & Events
Webcasts
Last webcast
Sep 8, 2026
View

Performance

5D 20D 120D MTD YTD
RNA +1.5% -20.2% -42.7% -0.2% —
SPY +1.3% +2.1% +9.0% +1.5% +13.5%
vs SPY +0.2% -22.3% -51.7% -1.7% —
Key facts CIK 2093101 CUSIP 04965N104 13F (30d) 6 filings 6 filers Visit website Investor relations